Glycopyrrolate/formoterol fumarate vs Olodaterol
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Chronic Obstructive Pulmonary Disease
Shared mechanism: Beta-2 adrenergic receptor · full Chronic Obstructive Pulmonary Disease pipeline
Glycopyrrolate/formoterol fumarate · Bevespi Aerosphere
Marketed by AstraZeneca
NCT03324607 · Phase 2/3 · completed
The study used a single treatment group without randomization, blinding, or a placebo or active comparator, and only 17 participants contributed to the primary imaging analysis. Its primary endpoints were surrogate MRI measures rather than established clinical outcomes, and the findings were mixed across those measures, so they provide limited evidence about Bevespi’s clinical effectiveness.
Reported efficacy
Ventilation Distribution as Measured by Ventilation Defect+Low Percent (Week 2); Barrier Uptake. (2 weeks); Red Blood Cell (RBC) Uptake (2 weeks): Ventilation Distribution as Measured by Ventilation Defect+Low Percent (Week 2): Treatment — Baseline: 57.8 percentage of total ventilation (Standard Deviation 8.4); Week 2: 52.5 percentage of total ventilation (Standard Deviation 10.6) (mixed)
Result source: NCT03324607
Olodaterol
Marketed by Boehringer Ingelheim
NCT00782210 · Phase 3 · completed
This was a randomized, double-blind, placebo-controlled phase 3 trial in 624 patients with COPD comparing two doses of olodaterol (5 mcg and 10 mcg once daily) against placebo. Both pre-specified co-primary endpoints—FEV1 AUC 0-3h and trough FEV1 at 12 weeks—were met for both doses, with large, statistically significant differences versus placebo (p<0.0001 for all primary comparisons). The trial was adequately powered, used a regulator-accepted lung function endpoint for COPD, and the primary results were clearly positive.
Reported efficacy
Forced Expiratory Volume in One Second (FEV1) Area Under Curve 0-3 Hour (h) (AUC 0-3h) Response at Day 85 (12 Weeks) (1 hour (h) and 10 minutes (min) prior to dose on the first day of randomized treatment (baseline) to -10 min, 5 min, 15 min, 30 min, 1 h, 2 h, and 3 h relative to dose on Day 85); Trough FEV1 Response at Day 85 (12 Weeks) (1 h and 10 min prior to dose on the first day of randomized treatment (baseline) and -1 h and - 10 mins prior to study drug at Day 85.): FEV1 AUC0-3h response at Day 85 (Week 12), difference from placebo: olodaterol 5 mcg +0.172 L (SE 0.019), P<0.0001; olodaterol 10 mcg +0.176 L (SE 0.019), P<0.0001 (study 1222.11, n=624). (met)
Result source: NCT00782210
Results for Chronic Obstructive Pulmonary Disease
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Glycopyrrolate/formoterol fumarate | Olodaterol |
|---|---|---|
| Moderate or severe exacerbations, annualised rate | —Not reported | 0.6 vs 0.7−0.1 vs placeboNCT007966533 other results
|
| Trough FEV1, change | —Not reported | 0.0 vs -0.1+0.1 vs placeboNCT00796653105 other results
|
| SGRQ total, change | —Not reported | 37.1 vs 42.0−4.9 vs placeboNCT0196435222 other results
|
| TDI focal score | —Not reported | 1.5 vs 1.1+0.4 vs placeboNCT0079665335 other results
|
Moderate or severe exacerbations, annualised rate
- Glycopyrrolate/formoterol fumarate
- —Not reported
- Olodaterol
- 0.6 vs 0.7−0.1 vs placeboNCT00796653
3 other results
- 0.7 vs 0.6 NCT00793624
- 0.5 vs 0.7 NCT00796653
- 0.7 vs 0.6 NCT00793624
Trough FEV1, change
- Glycopyrrolate/formoterol fumarate
- —Not reported
- Olodaterol
- 0.0 vs -0.1+0.1 vs placeboNCT00796653
105 other results
- 0.0 vs -0.1 NCT00793624
- 0.1 vs -0.0 NCT00782210
- 0.0 vs -0.0 NCT00782509
- -0.0 vs -0.1 NCT00796653
- 0.0 vs -0.1 NCT00793624
- 0.1 vs -0.0 NCT00782210
- 0.0 vs -0.0 NCT00782509
- 0.2 vs 0.0 NCT01964352
- 0.2 vs -0.0 NCT02006732
- 0.2 vs 0.0 NCT01964352
- 0.2 vs -0.0 NCT02006732
- 0.2 vs 0.1 NCT01696058
- 0.2 vs 0.1 NCT01694771
- 0.0 vs -0.7 NCT00782210
- 0.0 vs -0.1 NCT00782509
- -0.0 vs -0.1 NCT00796653
- -0.0 vs -0.1 NCT00793624
- 0.0 vs -0.1 NCT00782210
- 0.0 vs -0.0 NCT00782509
- 0.0 vs -0.0 NCT00796653
- 0.0 vs -0.0 NCT00793624
- 0.0 vs -0.1 NCT00782210
- -0.0 vs -0.0 NCT00782509
- 0.0 vs -0.0 NCT00796653
- 0.0 vs -0.0 NCT00793624
- 0.0 vs -0.1 NCT00782210
- 0.0 vs -0.0 NCT00782509
- 0.1 vs -0.0 NCT00782210
- 0.0 vs -0.0 NCT00782509
- 0.0 vs -0.0 NCT00796653
- 0.0 vs -0.0 NCT00793624
- 0.1 vs -0.0 NCT00796653
- 0.0 vs -0.0 NCT00793624
- 0.1 vs -0.0 NCT00782210
- 0.1 vs -0.0 NCT00782509
- 0.1 vs -0.0 NCT00796653
- 0.1 vs -0.0 NCT01040689
- 0.1 vs 0.0 NCT01040728
- 0.0 vs -0.0 NCT00793624
- 0.1 vs 0.0 NCT00932646
- 0.1 vs -0.0 NCT00782210
- 0.1 vs 0.0 NCT00782509
- 0.1 vs -0.0 NCT00796653
- 0.1 vs -0.0 NCT00793624
- 0.0 vs -0.7 NCT00782210
- 0.0 vs -0.1 NCT00782509
- -0.0 vs -0.1 NCT00796653
- 0.0 vs -0.1 NCT00793624
- 0.0 vs -0.1 NCT00782210
- 0.0 vs -0.0 NCT00782509
- 0.0 vs -0.0 NCT00796653
- 0.0 vs -0.0 NCT00793624
- 0.0 vs -0.1 NCT00782210
- 0.0 vs -0.0 NCT00782509
- 0.0 vs -0.0 NCT00796653
- 0.0 vs -0.0 NCT00793624
- 0.0 vs -0.1 NCT00782210
- 0.0 vs -0.0 NCT00782509
- 0.1 vs -0.0 NCT00782210
- 0.1 vs -0.0 NCT00782509
- 0.0 vs -0.0 NCT00796653
- 0.0 vs -0.0 NCT00793624
- 0.0 vs -0.0 NCT00796653
- 0.1 vs -0.0 NCT00793624
- 0.1 vs -0.0 NCT00782210
- 0.1 vs -0.0 NCT00782509
- 0.0 vs -0.0 NCT00796653
- 0.1 vs -0.0 NCT01040689
- 0.1 vs 0.0 NCT01040728
- 0.0 vs -0.0 NCT00793624
- 0.1 vs 0.0 NCT00932646
- 0.1 vs -0.0 NCT00782210
- 0.1 vs 0.0 NCT00782509
- 0.1 vs -0.0 NCT00796653
- 0.1 vs -0.0 NCT00793624
- 0.2 vs 0.1 NCT01969721
- 0.2 vs 0.1 NCT01969721
- 0.2 vs 0.1 NCT01536262
- 0.1 vs 0.1 NCT01536262
- 0.1 vs -0.0 NCT00824382
- 0.1 vs -0.0 NCT00452400
- 0.1 vs -0.0 NCT00824382
- 0.1 vs -0.0 NCT00452400
- 0.1 vs -0.0 NCT00452400
- 0.1 vs -0.0 NCT00824382
- 0.0 vs -0.0 NCT00452400
- 0.2 vs 0.1 NCT00696020
- 0.1 vs 0.1 NCT00696020
- 0.1 vs 0.1 NCT00696020
- 0.1 vs -0.0 NCT00824382
- 0.1 vs -0.0 NCT00452400
- 0.1 vs -0.0 NCT00452400
- 0.1 vs -0.1 NCT04223843
- 0.2 vs -0.1 NCT04223843
- 0.1 vs -0.0 NCT00824382
- 0.1 vs -0.0 NCT00452400
- 0.1 vs -0.0 NCT00452400
- 0.1 vs -0.0 NCT00452400
- 0.1 vs -0.0 NCT00452400
- 0.2 vs 0.1 NCT03673670
- 0.1 vs -0.0 NCT00824382
- 0.1 vs -0.0 NCT00452400
- 0.1 vs -0.0 NCT00452400
- 0.2 vs 0.1 NCT03673670
- 0.1 vs 0.1 NCT03240575
SGRQ total, change
- Glycopyrrolate/formoterol fumarate
- —Not reported
- Olodaterol
- 37.1 vs 42.0−4.9 vs placeboNCT01964352
22 other results
- 38.0 vs 42.6 NCT02006732
- 37.6 vs 42.3 NCT02006732
- 37.9 vs 42.0 NCT01964352
- 38.9 vs 42.6 NCT02006732
- 38.4 vs 42.3 NCT02006732
- 41.2 vs 43.1 NCT01696058
- 38.8 vs 39.9 NCT00796653
- 36.9 vs 40.4 NCT00793624
- 38.6 vs 42.1 NCT00796653
- 38.2 vs 41.6 NCT00796653
- 37.7 vs 41.1 NCT00793624
- 38.2 vs 41.6 NCT00793624
- 40.2 vs 42.7 NCT00796653
- 37.0 vs 42.1 NCT00793624
- 39.6 vs 39.9 NCT00796653
- 38.5 vs 40.4 NCT00793624
- 39.0 vs 42.1 NCT00796653
- 38.8 vs 41.6 NCT00796653
- 38.6 vs 41.1 NCT00793624
- 38.8 vs 41.6 NCT00793624
- 40.1 vs 42.7 NCT00796653
- 39.3 vs 42.1 NCT00793624
TDI focal score
- Glycopyrrolate/formoterol fumarate
- —Not reported
- Olodaterol
- 1.5 vs 1.1+0.4 vs placeboNCT00796653
35 other results
- 2.0 vs 1.5 NCT00796653
- 2.1 vs 2.0 NCT00793624
- 2.0 vs 1.5 NCT00793624
- 1.5 vs 1.1 NCT00796653
- 2.0 vs 1.5 NCT00796653
- 2.2 vs 2.0 NCT00793624
- 2.0 vs 1.5 NCT00793624
- 1.8 vs 1.1 NCT00796653
- 2.3 vs 1.9 NCT00793624
- 1.5 vs 1.1 NCT00796653
- 1.9 vs 2.0 NCT00793624
- 1.5 vs 1.2 NCT00796653
- 1.7 vs 1.7 NCT00793624
- 1.5 vs 1.0 NCT00796653
- 2.1 vs 1.7 NCT00793624
- 1.7 vs 1.1 NCT00796653
- 2.0 vs 1.4 NCT00793624
- 1.7 vs 1.0 NCT00796653
- 1.7 vs 1.0 NCT00793624
- 1.5 vs 1.1 NCT00796653
- 2.0 vs 1.9 NCT00793624
- 1.4 vs 1.1 NCT00796653
- 1.8 vs 2.0 NCT00793624
- 1.7 vs 1.2 NCT00796653
- 1.9 vs 1.7 NCT00793624
- 1.5 vs 1.0 NCT00796653
- 1.9 vs 1.7 NCT00793624
- 1.7 vs 1.1 NCT00796653
- 1.5 vs 0.3 NCT02006732
- 1.7 vs 0.1 NCT02006732
- 1.8 vs 1.4 NCT00793624
- 1.4 vs 1.0 NCT00796653
- 1.6 vs 1.0 NCT00793624
- 1.6 vs 0.3 NCT02006732
- 1.7 vs 0.1 NCT02006732
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
1 other shared endpoint and safety
Coverage. Glycopyrrolate/formoterol fumarate: 3 of 5 rows · Olodaterol: 5 of 5 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Glycopyrrolate/formoterol fumarate | Olodaterol |
|---|---|---|
| Exercise Endurance Time Seconds absolute value · seconds | 382.5 vs 328 placebo secondsa,b,c,d NCT03081156 · Phase 4 · registry result, not featured evidence | 324.21 vs 243.3 placebo seconds @ 12wk5/5 μge,a,b,c,d NCT02085161 · Phase 3 · registry result, not featured evidence · combination show 1 more dose302.61 vs 243.3 placebo seconds @ 12wk5/5 μg NCT02085161 · Phase 3 · registry result, not featured evidence · combination |
| Dropout rate | 0%f NCT03324607 · Phase 2/3 · combination · Chronic Obstructive Pulmonary Disease · phase 2/3 show 1 more result— NCT03081156 · Phase 4 · registry result, not featured evidence | —10 mcgg NCT00782210 · Phase 3 show 77 more results16.9%10 mcg qd NCT00782210 · Phase 3 —5 mcg NCT00782210 · Phase 3 16.8%5 mcg qd NCT00782210 · Phase 3 —10 mcg NCT00782509 · Phase 3 16.6%10 mcg qd NCT00782509 · Phase 3 —5 mcg NCT00782509 · Phase 3 11.5%5 mcg qd NCT00782509 · Phase 3 15.4%10 mcg qd NCT00796653 · Phase 3 15.9%5 mcg qd NCT00796653 · Phase 3 —5μg/5μg NCT04223843 · Phase 4 · registry result, not featured evidence · combination 0%5μg/5μg NCT04223843 · Phase 4 · registry result, not featured evidence · combination 0%5μg/5μg NCT04223843 · Phase 4 · registry result, not featured evidence · combination —5μg/5μg NCT03240575 · Phase 4 · registry result, not featured evidence · combination 0%5μg/5μg NCT03240575 · Phase 4 · registry result, not featured evidence · combination 1.4%5μg/5μg NCT03240575 · Phase 4 · registry result, not featured evidence · combination —5/5 μg NCT02853123 · Phase 4 · registry result, not featured evidence · combination 0%5/5 mcg NCT02683109 · Phase 4 · registry result, not featured evidence —5/5 NCT02629965 · Phase 3 · registry result, not featured evidence · combination 13.2%5/5 μg NCT02085161 · Phase 3 · registry result, not featured evidence · combination 6.6%5/5 μg NCT02085161 · Phase 3 · registry result, not featured evidence · combination —2.5/5 NCT01969721 · Phase 3 · registry result, not featured evidence · combination —5/5 NCT01969721 · Phase 3 · registry result, not featured evidence · combination 3.9%5 μg + 5 μg NCT01964352 · Phase 3 · registry result, not featured evidence · combination 3%2.5 μg + 5 μg NCT01964352 · Phase 3 · registry result, not featured evidence · combination 2%5 μg + 5 μg NCT02006732 · Phase 3 · registry result, not featured evidence · combination —5 μg + 5 μg NCT02006732 · Phase 3 · registry result, not featured evidence · combination —2.5 μg + 5 μg NCT02006732 · Phase 3 · registry result, not featured evidence · combination 4.5%2.5 μg + 5 μg NCT02006732 · Phase 3 · registry result, not featured evidence · combination 7.6%5 μg and 18 μg NCT01696058 · Phase 3 · registry result, not featured evidence · combination 5.3%2.5 / 5.0 µg NCT01525615 · Phase 3 · registry result, not featured evidence · combination —2.5 / 5.0 μg NCT01525615 · Phase 3 · registry result, not featured evidence · combination 4.3%5.0 / 5.0 µg NCT01525615 · Phase 3 · registry result, not featured evidence · combination —5.0 / 5.0 μg NCT01525615 · Phase 3 · registry result, not featured evidence · combination 5%2.5 / 5 μg NCT01536262 · Phase 3 · registry result, not featured evidence · combination 4.9%5 / 5 μg NCT01536262 · Phase 3 · registry result, not featured evidence · combination 7.1%5µg olodaterol + 18µg tiotropium NCT01694771 · Phase 3 · registry result, not featured evidence —10 mcg NCT01040130 · Phase 3 · registry result, not featured evidence —5 mcg NCT01040130 · Phase 3 · registry result, not featured evidence —10 mcg NCT01040793 · Phase 3 · registry result, not featured evidence —5 mcg NCT01040793 · Phase 3 · registry result, not featured evidence —10 mcg NCT01040689 · Phase 3 · registry result, not featured evidence —5 mcg NCT01040689 · Phase 3 · registry result, not featured evidence —10 mcg NCT01040728 · Phase 3 · registry result, not featured evidence —5 mcg NCT01040728 · Phase 3 · registry result, not featured evidence 17.3%10 mcg qd NCT00793624 · Phase 3 · registry result, not featured evidence 15.9%5 mcg qd NCT00793624 · Phase 3 · registry result, not featured evidence —10 mcg NCT00932646 · Phase 3 · registry result, not featured evidence —5 mcg NCT00932646 · Phase 3 · registry result, not featured evidence —6 mg NCT03673670 · Phase 2 · registry result, not featured evidence · combination —1.5 mg NCT03673670 · Phase 2 · registry result, not featured evidence · combination — NCT02030535 · Phase 2 · registry result, not featured evidence · combination —10 mcg NCT01040403 · Phase 2 · registry result, not featured evidence —5 mcg NCT01040403 · Phase 2 · registry result, not featured evidence —tiotropium 5 mcg + olodaterol 10 mcg NCT01040403 · Phase 2 · registry result, not featured evidence · combination —tiotropium 5 mcg + olodaterol 5 mcg NCT01040403 · Phase 2 · registry result, not featured evidence · combination —tiotropium 2.5 mcg + olodaterol 10 mcg NCT01040403 · Phase 2 · registry result, not featured evidence · combination —tiotropium 2.5 mcg + olodaterol 5 mcg NCT01040403 · Phase 2 · registry result, not featured evidence · combination —tiotropium 1.25 mcg + olodaterol 10 mcg NCT01040403 · Phase 2 · registry result, not featured evidence · combination —tiotropium 1.25 mcg + olodaterol 5 mcg NCT01040403 · Phase 2 · registry result, not featured evidence · combination 5.8%10mcg NCT00824382 · Phase 2 · registry result, not featured evidence 3.8%5mcg NCT00824382 · Phase 2 · registry result, not featured evidence 2.4%2mcg NCT00824382 · Phase 2 · registry result, not featured evidence —10 mcg qd NCT00846768 · Phase 2 · registry result, not featured evidence —5 mcg Bid NCT00846768 · Phase 2 · registry result, not featured evidence —5 mcg qd NCT00846768 · Phase 2 · registry result, not featured evidence —2 mcg Bid NCT00846768 · Phase 2 · registry result, not featured evidence 4.5%5/10 μg NCT00696020 · Phase 2 · registry result, not featured evidence · combination 2.2%5/2 μg NCT00696020 · Phase 2 · registry result, not featured evidence · combination 3.2%5/5 μg NCT00696020 · Phase 2 · registry result, not featured evidence · combination —10 mcg NCT00452400 · Phase 2 · registry result, not featured evidence 1.2%10 mcg qd NCT00452400 · Phase 2 · registry result, not featured evidence —5 mcg NCT00452400 · Phase 2 · registry result, not featured evidence 8.8%5 mcg qd NCT00452400 · Phase 2 · registry result, not featured evidence —20 mcg NCT00452400 · Phase 2 · registry result, not featured evidence 3.8%20 mcg qd NCT00452400 · Phase 2 · registry result, not featured evidence —2 mcg NCT00452400 · Phase 2 · registry result, not featured evidence 1.2%2 mcg qd NCT00452400 · Phase 2 · registry result, not featured evidence |
| Discontinued due to AEs | —f NCT03324607 · Phase 2/3 · combination · Chronic Obstructive Pulmonary Disease · phase 2/3 show 1 more result— NCT03081156 · Phase 4 · registry result, not featured evidence | —10 mcgg NCT00782210 · Phase 3 show 77 more results7.7%10 mcg qd NCT00782210 · Phase 3 —5 mcg NCT00782210 · Phase 3 8.2%5 mcg qd NCT00782210 · Phase 3 —10 mcg NCT00782509 · Phase 3 9.2%10 mcg qd NCT00782509 · Phase 3 —5 mcg NCT00782509 · Phase 3 4.8%5 mcg qd NCT00782509 · Phase 3 6.8%10 mcg qd NCT00796653 · Phase 3 6.9%5 mcg qd NCT00796653 · Phase 3 —5μg/5μg NCT04223843 · Phase 4 · registry result, not featured evidence · combination —5μg/5μg NCT04223843 · Phase 4 · registry result, not featured evidence · combination —5μg/5μg NCT04223843 · Phase 4 · registry result, not featured evidence · combination —5μg/5μg NCT03240575 · Phase 4 · registry result, not featured evidence · combination 0%5μg/5μg NCT03240575 · Phase 4 · registry result, not featured evidence · combination 0%5μg/5μg NCT03240575 · Phase 4 · registry result, not featured evidence · combination —5/5 μg NCT02853123 · Phase 4 · registry result, not featured evidence · combination 0%5/5 mcg NCT02683109 · Phase 4 · registry result, not featured evidence —5/5 NCT02629965 · Phase 3 · registry result, not featured evidence · combination 6.6%5/5 μg NCT02085161 · Phase 3 · registry result, not featured evidence · combination 5.3%5/5 μg NCT02085161 · Phase 3 · registry result, not featured evidence · combination —2.5/5 NCT01969721 · Phase 3 · registry result, not featured evidence · combination —5/5 NCT01969721 · Phase 3 · registry result, not featured evidence · combination 1.5%5 μg + 5 μg NCT01964352 · Phase 3 · registry result, not featured evidence · combination 2%2.5 μg + 5 μg NCT01964352 · Phase 3 · registry result, not featured evidence · combination 1%5 μg + 5 μg NCT02006732 · Phase 3 · registry result, not featured evidence · combination —5 μg + 5 μg NCT02006732 · Phase 3 · registry result, not featured evidence · combination —2.5 μg + 5 μg NCT02006732 · Phase 3 · registry result, not featured evidence · combination 2%2.5 μg + 5 μg NCT02006732 · Phase 3 · registry result, not featured evidence · combination 3.7%5 μg and 18 μg NCT01696058 · Phase 3 · registry result, not featured evidence · combination 5.3%2.5 / 5.0 µg NCT01525615 · Phase 3 · registry result, not featured evidence · combination —2.5 / 5.0 μg NCT01525615 · Phase 3 · registry result, not featured evidence · combination 3.6%5.0 / 5.0 µg NCT01525615 · Phase 3 · registry result, not featured evidence · combination —5.0 / 5.0 μg NCT01525615 · Phase 3 · registry result, not featured evidence · combination 2.5%2.5 / 5 μg NCT01536262 · Phase 3 · registry result, not featured evidence · combination 4.9%5 / 5 μg NCT01536262 · Phase 3 · registry result, not featured evidence · combination 3.2%5µg olodaterol + 18µg tiotropium NCT01694771 · Phase 3 · registry result, not featured evidence —10 mcg NCT01040130 · Phase 3 · registry result, not featured evidence —5 mcg NCT01040130 · Phase 3 · registry result, not featured evidence —10 mcg NCT01040793 · Phase 3 · registry result, not featured evidence —5 mcg NCT01040793 · Phase 3 · registry result, not featured evidence —10 mcg NCT01040689 · Phase 3 · registry result, not featured evidence —5 mcg NCT01040689 · Phase 3 · registry result, not featured evidence —10 mcg NCT01040728 · Phase 3 · registry result, not featured evidence —5 mcg NCT01040728 · Phase 3 · registry result, not featured evidence 6.7%10 mcg qd NCT00793624 · Phase 3 · registry result, not featured evidence 7%5 mcg qd NCT00793624 · Phase 3 · registry result, not featured evidence —10 mcg NCT00932646 · Phase 3 · registry result, not featured evidence —5 mcg NCT00932646 · Phase 3 · registry result, not featured evidence —6 mg NCT03673670 · Phase 2 · registry result, not featured evidence · combination —1.5 mg NCT03673670 · Phase 2 · registry result, not featured evidence · combination — NCT02030535 · Phase 2 · registry result, not featured evidence · combination —10 mcg NCT01040403 · Phase 2 · registry result, not featured evidence —5 mcg NCT01040403 · Phase 2 · registry result, not featured evidence —tiotropium 5 mcg + olodaterol 10 mcg NCT01040403 · Phase 2 · registry result, not featured evidence · combination —tiotropium 5 mcg + olodaterol 5 mcg NCT01040403 · Phase 2 · registry result, not featured evidence · combination —tiotropium 2.5 mcg + olodaterol 10 mcg NCT01040403 · Phase 2 · registry result, not featured evidence · combination —tiotropium 2.5 mcg + olodaterol 5 mcg NCT01040403 · Phase 2 · registry result, not featured evidence · combination —tiotropium 1.25 mcg + olodaterol 10 mcg NCT01040403 · Phase 2 · registry result, not featured evidence · combination —tiotropium 1.25 mcg + olodaterol 5 mcg NCT01040403 · Phase 2 · registry result, not featured evidence · combination 4.7%10mcg NCT00824382 · Phase 2 · registry result, not featured evidence 1.3%5mcg NCT00824382 · Phase 2 · registry result, not featured evidence 1.2%2mcg NCT00824382 · Phase 2 · registry result, not featured evidence —10 mcg qd NCT00846768 · Phase 2 · registry result, not featured evidence —5 mcg Bid NCT00846768 · Phase 2 · registry result, not featured evidence —5 mcg qd NCT00846768 · Phase 2 · registry result, not featured evidence —2 mcg Bid NCT00846768 · Phase 2 · registry result, not featured evidence 1.1%5/10 μg NCT00696020 · Phase 2 · registry result, not featured evidence · combination 1.1%5/2 μg NCT00696020 · Phase 2 · registry result, not featured evidence · combination 2.2%5/5 μg NCT00696020 · Phase 2 · registry result, not featured evidence · combination —10 mcg NCT00452400 · Phase 2 · registry result, not featured evidence 0%10 mcg qd NCT00452400 · Phase 2 · registry result, not featured evidence —5 mcg NCT00452400 · Phase 2 · registry result, not featured evidence 6.3%5 mcg qd NCT00452400 · Phase 2 · registry result, not featured evidence —20 mcg NCT00452400 · Phase 2 · registry result, not featured evidence 2.5%20 mcg qd NCT00452400 · Phase 2 · registry result, not featured evidence —2 mcg NCT00452400 · Phase 2 · registry result, not featured evidence 1.2%2 mcg qd NCT00452400 · Phase 2 · registry result, not featured evidence |
| Serious AEs | 0%f NCT03324607 · Phase 2/3 · combination · Chronic Obstructive Pulmonary Disease · phase 2/3 show 1 more result12.5% NCT03081156 · Phase 4 · registry result, not featured evidence | 20.8%10 mcgg NCT00782210 · Phase 3 show 77 more results—10 mcg qd NCT00782210 · Phase 3 18.8%5 mcg NCT00782210 · Phase 3 —5 mcg qd NCT00782210 · Phase 3 17.1%10 mcg NCT00782509 · Phase 3 —10 mcg qd NCT00782509 · Phase 3 15.3%5 mcg NCT00782509 · Phase 3 —5 mcg qd NCT00782509 · Phase 3 17.5%10 mcg qd NCT00796653 · Phase 3 14.7%5 mcg qd NCT00796653 · Phase 3 1.9%5μg/5μg NCT04223843 · Phase 4 · registry result, not featured evidence · combination —5μg/5μg NCT04223843 · Phase 4 · registry result, not featured evidence · combination —5μg/5μg NCT04223843 · Phase 4 · registry result, not featured evidence · combination 3.9%5μg/5μg NCT03240575 · Phase 4 · registry result, not featured evidence · combination —5μg/5μg NCT03240575 · Phase 4 · registry result, not featured evidence · combination —5μg/5μg NCT03240575 · Phase 4 · registry result, not featured evidence · combination 4.8%5/5 μg NCT02853123 · Phase 4 · registry result, not featured evidence · combination 1.8%5/5 mcg NCT02683109 · Phase 4 · registry result, not featured evidence 3.9%5/5 NCT02629965 · Phase 3 · registry result, not featured evidence · combination 10.5%5/5 μg NCT02085161 · Phase 3 · registry result, not featured evidence · combination 3.9%5/5 μg NCT02085161 · Phase 3 · registry result, not featured evidence · combination 2.8%2.5/5 NCT01969721 · Phase 3 · registry result, not featured evidence · combination 3.2%5/5 NCT01969721 · Phase 3 · registry result, not featured evidence · combination 4.9%5 μg + 5 μg NCT01964352 · Phase 3 · registry result, not featured evidence · combination 2%2.5 μg + 5 μg NCT01964352 · Phase 3 · registry result, not featured evidence · combination —5 μg + 5 μg NCT02006732 · Phase 3 · registry result, not featured evidence · combination 3%5 μg + 5 μg NCT02006732 · Phase 3 · registry result, not featured evidence · combination 2%2.5 μg + 5 μg NCT02006732 · Phase 3 · registry result, not featured evidence · combination —2.5 μg + 5 μg NCT02006732 · Phase 3 · registry result, not featured evidence · combination 4.2%5 μg and 18 μg NCT01696058 · Phase 3 · registry result, not featured evidence · combination —2.5 / 5.0 µg NCT01525615 · Phase 3 · registry result, not featured evidence · combination 6.8%2.5 / 5.0 μg NCT01525615 · Phase 3 · registry result, not featured evidence · combination —5.0 / 5.0 µg NCT01525615 · Phase 3 · registry result, not featured evidence · combination 2.9%5.0 / 5.0 μg NCT01525615 · Phase 3 · registry result, not featured evidence · combination 15%2.5 / 5 μg NCT01536262 · Phase 3 · registry result, not featured evidence · combination 7.3%5 / 5 μg NCT01536262 · Phase 3 · registry result, not featured evidence · combination 7.1%5µg olodaterol + 18µg tiotropium NCT01694771 · Phase 3 · registry result, not featured evidence 2.1%10 mcg NCT01040130 · Phase 3 · registry result, not featured evidence 2%5 mcg NCT01040130 · Phase 3 · registry result, not featured evidence 2%10 mcg NCT01040793 · Phase 3 · registry result, not featured evidence 5.3%5 mcg NCT01040793 · Phase 3 · registry result, not featured evidence 0%10 mcg NCT01040689 · Phase 3 · registry result, not featured evidence 1%5 mcg NCT01040689 · Phase 3 · registry result, not featured evidence 7.1%10 mcg NCT01040728 · Phase 3 · registry result, not featured evidence 2.6%5 mcg NCT01040728 · Phase 3 · registry result, not featured evidence 11.6%10 mcg qd NCT00793624 · Phase 3 · registry result, not featured evidence 14.5%5 mcg qd NCT00793624 · Phase 3 · registry result, not featured evidence 3.2%10 mcg NCT00932646 · Phase 3 · registry result, not featured evidence 4.3%5 mcg NCT00932646 · Phase 3 · registry result, not featured evidence 1.4%6 mg NCT03673670 · Phase 2 · registry result, not featured evidence · combination 0%1.5 mg NCT03673670 · Phase 2 · registry result, not featured evidence · combination 0% NCT02030535 · Phase 2 · registry result, not featured evidence · combination 1.8%10 mcg NCT01040403 · Phase 2 · registry result, not featured evidence 3.7%5 mcg NCT01040403 · Phase 2 · registry result, not featured evidence 0%tiotropium 5 mcg + olodaterol 10 mcg NCT01040403 · Phase 2 · registry result, not featured evidence · combination 0.9%tiotropium 5 mcg + olodaterol 5 mcg NCT01040403 · Phase 2 · registry result, not featured evidence · combination 4.5%tiotropium 2.5 mcg + olodaterol 10 mcg NCT01040403 · Phase 2 · registry result, not featured evidence · combination 2.7%tiotropium 2.5 mcg + olodaterol 5 mcg NCT01040403 · Phase 2 · registry result, not featured evidence · combination 0.9%tiotropium 1.25 mcg + olodaterol 10 mcg NCT01040403 · Phase 2 · registry result, not featured evidence · combination 0.9%tiotropium 1.25 mcg + olodaterol 5 mcg NCT01040403 · Phase 2 · registry result, not featured evidence · combination 3.5%10mcg NCT00824382 · Phase 2 · registry result, not featured evidence 1.3%5mcg NCT00824382 · Phase 2 · registry result, not featured evidence 3.6%2mcg NCT00824382 · Phase 2 · registry result, not featured evidence 0%10 mcg qd NCT00846768 · Phase 2 · registry result, not featured evidence 0%5 mcg Bid NCT00846768 · Phase 2 · registry result, not featured evidence 0%5 mcg qd NCT00846768 · Phase 2 · registry result, not featured evidence 2.1%2 mcg Bid NCT00846768 · Phase 2 · registry result, not featured evidence 0%5/10 μg NCT00696020 · Phase 2 · registry result, not featured evidence · combination 3.4%5/2 μg NCT00696020 · Phase 2 · registry result, not featured evidence · combination 1.1%5/5 μg NCT00696020 · Phase 2 · registry result, not featured evidence · combination 2.3%10 mcg NCT00452400 · Phase 2 · registry result, not featured evidence —10 mcg qd NCT00452400 · Phase 2 · registry result, not featured evidence 2.5%5 mcg NCT00452400 · Phase 2 · registry result, not featured evidence —5 mcg qd NCT00452400 · Phase 2 · registry result, not featured evidence 2.5%20 mcg NCT00452400 · Phase 2 · registry result, not featured evidence —20 mcg qd NCT00452400 · Phase 2 · registry result, not featured evidence 2.5%2 mcg NCT00452400 · Phase 2 · registry result, not featured evidence —2 mcg qd NCT00452400 · Phase 2 · registry result, not featured evidence |
| Most frequent reported AEs | — | 10 mcgg chronic obstructive pulmonary disease 23.7% (placebo 27.3%) nasopharyngitis 6.3% (placebo 6.2%) upper respiratory tract infection 6.3% (placebo 7.2%) NCT00782210 · Phase 3 show 57 more results5 mcg chronic obstructive pulmonary disease 19.2% (placebo 27.3%) nasopharyngitis 10.1% (placebo 6.2%) upper respiratory tract infection 10.1% (placebo 7.2%) NCT00782210 · Phase 3 10 mcg chronic obstructive pulmonary disease 21.7% (placebo 19.9%) nasopharyngitis 11.5% (placebo 8.3%) upper respiratory tract infection 10.1% (placebo 7.9%) NCT00782509 · Phase 3 5 mcg chronic obstructive pulmonary disease 18.7% (placebo 19.9%) upper respiratory tract infection 9.6% (placebo 7.9%) nasopharyngitis 9.1% (placebo 8.3%) NCT00782509 · Phase 3 10 mcg qd chronic obstructive pulmonary disease 20.5% (placebo 21.7%) nasopharyngitis 12% (placebo 9.4%) upper respiratory tract infection 6.4% (placebo 7.7%) NCT00796653 · Phase 3 5 mcg qd chronic obstructive pulmonary disease 17.2% (placebo 21.7%) nasopharyngitis 15.5% (placebo 9.4%) upper respiratory tract infection 6% (placebo 7.7%) NCT00796653 · Phase 3 5μg/5μg chronic obstructive pulmonary disease 5.3% NCT03240575 · Phase 4 · registry result, not featured evidence · combination 5/5 μg chronic obstructive pulmonary disease 13.3% viral upper respiratory tract infection 13.3% cough 4.8% NCT02853123 · Phase 4 · registry result, not featured evidence · combination 5/5 mcg chronic obstructive pulmonary disease 8.1% NCT02683109 · Phase 4 · registry result, not featured evidence 5/5 viral upper respiratory tract infection 10% NCT02629965 · Phase 3 · registry result, not featured evidence · combination 5/5 μg chronic obstructive pulmonary disease 17.1% (placebo 21.3%) nasopharyngitis 13.2% (placebo 10.7%) dyspnoea 2.6% (placebo 2.7%) NCT02085161 · Phase 3 · registry result, not featured evidence · combination 5/5 μg chronic obstructive pulmonary disease 15.8% (placebo 21.3%) nasopharyngitis 5.3% (placebo 10.7%) back pain 2.6% (placebo 5.3%) NCT02085161 · Phase 3 · registry result, not featured evidence · combination 2.5/5 nasopharyngitis 5.6% chronic obstructive pulmonary disease 4.7% NCT01969721 · Phase 3 · registry result, not featured evidence · combination 5/5 chronic obstructive pulmonary disease 8.1% nasopharyngitis 5.4% NCT01969721 · Phase 3 · registry result, not featured evidence · combination 5 μg + 5 μg chronic obstructive pulmonary disease 4.4% (placebo 9.8%) nasopharyngitis 3.4% (placebo 5.9%) NCT01964352 · Phase 3 · registry result, not featured evidence · combination 2.5 μg + 5 μg chronic obstructive pulmonary disease 7.9% (placebo 9.8%) nasopharyngitis 4.5% (placebo 5.9%) NCT01964352 · Phase 3 · registry result, not featured evidence · combination 5 μg + 5 μg chronic obstructive pulmonary disease 4.5% (placebo 6.9%) cough 1.5% (placebo 5.9%) dyspnoea 1% (placebo 6.9%) NCT02006732 · Phase 3 · registry result, not featured evidence · combination 2.5 μg + 5 μg chronic obstructive pulmonary disease 8.4% (placebo 6.9%) cough 2.5% (placebo 5.9%) dyspnoea 2% (placebo 6.9%) NCT02006732 · Phase 3 · registry result, not featured evidence · combination 5 μg and 18 μg chronic obstructive pulmonary disease 8.5% (placebo 7.7%) NCT01696058 · Phase 3 · registry result, not featured evidence · combination 2.5 / 5.0 μg chronic obstructive pulmonary disease 7.5% (placebo 11.4%) cough 6.8% (placebo 6.1%) nasopharyngitis 6.8% (placebo 4.5%) NCT01525615 · Phase 3 · registry result, not featured evidence · combination 5.0 / 5.0 μg chronic obstructive pulmonary disease 7.2% (placebo 11.4%) nasopharyngitis 2.9% (placebo 4.5%) cough 1.4% (placebo 6.1%) NCT01525615 · Phase 3 · registry result, not featured evidence · combination 2.5 / 5 μg nasopharyngitis 27.5% bronchitis 12.5% chronic obstructive pulmonary disease 10% NCT01536262 · Phase 3 · registry result, not featured evidence · combination 5 / 5 μg nasopharyngitis 26.8% chronic obstructive pulmonary disease 17.1% bronchitis 14.6% NCT01536262 · Phase 3 · registry result, not featured evidence · combination 5µg olodaterol + 18µg tiotropium chronic obstructive pulmonary disease 10.6% NCT01694771 · Phase 3 · registry result, not featured evidence 10 mcg chronic obstructive pulmonary disease 3.5% (placebo 5.6%) NCT01040130 · Phase 3 · registry result, not featured evidence 5 mcg chronic obstructive pulmonary disease 6.8% (placebo 5.6%) NCT01040130 · Phase 3 · registry result, not featured evidence 10 mcg chronic obstructive pulmonary disease 2.7% (placebo 6%) NCT01040793 · Phase 3 · registry result, not featured evidence 5 mcg chronic obstructive pulmonary disease 5.3% (placebo 6%) NCT01040793 · Phase 3 · registry result, not featured evidence 10 mcg nasopharyngitis 4% (placebo 7.8%) chronic obstructive pulmonary disease 2% (placebo 3.9%) NCT01040689 · Phase 3 · registry result, not featured evidence 5 mcg chronic obstructive pulmonary disease 7.9% (placebo 3.9%) nasopharyngitis 5.9% (placebo 7.8%) NCT01040689 · Phase 3 · registry result, not featured evidence 10 mcg nasopharyngitis 3.5% (placebo 3.7%) chronic obstructive pulmonary disease 2.7% (placebo 3.7%) NCT01040728 · Phase 3 · registry result, not featured evidence 5 mcg nasopharyngitis 7% (placebo 3.7%) chronic obstructive pulmonary disease 5.2% (placebo 3.7%) NCT01040728 · Phase 3 · registry result, not featured evidence 10 mcg qd chronic obstructive pulmonary disease 27.6% (placebo 22.7%) nasopharyngitis 11.1% (placebo 6.7%) cough 5.8% (placebo 3.1%) NCT00793624 · Phase 3 · registry result, not featured evidence 5 mcg qd chronic obstructive pulmonary disease 29.5% (placebo 22.7%) nasopharyngitis 9.7% (placebo 6.7%) upper respiratory tract infection 7.5% (placebo 6.7%) NCT00793624 · Phase 3 · registry result, not featured evidence 10 mcg chronic obstructive pulmonary disease 7.4% (placebo 5.3%) upper respiratory tract infection 5.3% (placebo 4.3%) NCT00932646 · Phase 3 · registry result, not featured evidence 5 mcg chronic obstructive pulmonary disease 5.4% (placebo 5.3%) upper respiratory tract infection 4.3% (placebo 4.3%) NCT00932646 · Phase 3 · registry result, not featured evidence 6 mg headache 6.8% (placebo 1.3%) ventricular extrasystoles 4.1% (placebo 0%) chronic obstructive pulmonary disease 2.7% (placebo 1.3%) NCT03673670 · Phase 2 · registry result, not featured evidence · combination 1.5 mg headache 6.7% (placebo 1.3%) ventricular extrasystoles 2.7% (placebo 0%) accelerated idioventricular rhythm 1.3% (placebo 0%) NCT03673670 · Phase 2 · registry result, not featured evidence · combination nasopharyngitis 1.9% (placebo 5.7%) NCT02030535 · Phase 2 · registry result, not featured evidence · combination 10 mcg nasopharyngitis 6.4% chronic obstructive pulmonary disease 5.5% NCT01040403 · Phase 2 · registry result, not featured evidence 5 mcg nasopharyngitis 10.2% chronic obstructive pulmonary disease 5.6% NCT01040403 · Phase 2 · registry result, not featured evidence tiotropium 5 mcg + olodaterol 10 mcg chronic obstructive pulmonary disease 3.6% nasopharyngitis 1.8% NCT01040403 · Phase 2 · registry result, not featured evidence · combination tiotropium 5 mcg + olodaterol 5 mcg chronic obstructive pulmonary disease 7.3% nasopharyngitis 2.8% NCT01040403 · Phase 2 · registry result, not featured evidence · combination tiotropium 2.5 mcg + olodaterol 10 mcg nasopharyngitis 3.6% chronic obstructive pulmonary disease 2.7% NCT01040403 · Phase 2 · registry result, not featured evidence · combination tiotropium 2.5 mcg + olodaterol 5 mcg nasopharyngitis 7.1% chronic obstructive pulmonary disease 2.7% NCT01040403 · Phase 2 · registry result, not featured evidence · combination tiotropium 1.25 mcg + olodaterol 10 mcg nasopharyngitis 7.3% chronic obstructive pulmonary disease 6.4% NCT01040403 · Phase 2 · registry result, not featured evidence · combination tiotropium 1.25 mcg + olodaterol 5 mcg nasopharyngitis 11% chronic obstructive pulmonary disease 3.7% NCT01040403 · Phase 2 · registry result, not featured evidence · combination 10mcg nasopharyngitis 5.8% (placebo 3.8%) myalgia 0% (placebo 5.1%) NCT00824382 · Phase 2 · registry result, not featured evidence 5mcg nasopharyngitis 3.8% (placebo 3.8%) myalgia 0% (placebo 5.1%) NCT00824382 · Phase 2 · registry result, not featured evidence 2mcg nasopharyngitis 10.7% (placebo 3.8%) myalgia 0% (placebo 5.1%) NCT00824382 · Phase 2 · registry result, not featured evidence 10 mcg qd nasopharyngitis 6.5% dyspnoea 0% NCT00846768 · Phase 2 · registry result, not featured evidence 5 mcg Bid nasopharyngitis 6.5% dyspnoea 2.2% NCT00846768 · Phase 2 · registry result, not featured evidence 5 mcg qd dyspnoea 6.4% nasopharyngitis 2.1% NCT00846768 · Phase 2 · registry result, not featured evidence 2 mcg Bid nasopharyngitis 2.1% dyspnoea 0% NCT00846768 · Phase 2 · registry result, not featured evidence 10 mcg nasopharyngitis 4.7% (placebo 1.3%) headache 3.5% (placebo 5.1%) cough 2.3% (placebo 2.5%) NCT00452400 · Phase 2 · registry result, not featured evidence 5 mcg cough 7.5% (placebo 2.5%) nasopharyngitis 7.5% (placebo 1.3%) dyspnoea 2.5% (placebo 7.6%) NCT00452400 · Phase 2 · registry result, not featured evidence 20 mcg dyspnoea 3.8% (placebo 7.6%) cough 2.5% (placebo 2.5%) nasopharyngitis 2.5% (placebo 1.3%) NCT00452400 · Phase 2 · registry result, not featured evidence 2 mcg cough 4.9% (placebo 2.5%) dyspnoea 3.7% (placebo 7.6%) headache 3.7% (placebo 5.1%) NCT00452400 · Phase 2 · registry result, not featured evidence |
Notes
- aTrial phases differ: Phase 3 versus Phase 4.
- bPopulation comparability has not been reviewed for both studies.
- cTreatment context has not been resolved for both arms.
- dThe assessment timepoint is not available for both results.
- eThis study reports multiple eligible drug arms; no representative arm has been reviewed.
- fPopulation comparability has not been reviewed for 1 of these studies.
- gPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Glycopyrrolate/formoterol fumarate
Olodaterol
show 68 more results
show 106 more results
show 17 more results
show 84 more results
show 59 more results
show 90 more results
show 58 more results
show 9 more results
show 15 more results
show 15 more results
show 15 more results
show 15 more results
+ 96 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Glycopyrrolate/formoterol fumarate's landscape · Olodaterol's landscape